Mission

SIR Foundation is a scientific foundation dedicated to fostering research in interventional radiology for the purposes of advancing scientific knowledge, increasing the number of skilled investigators, and developing innovative therapies that lead to improved patient care and quality of life. The Foundation is committed to fostering the development and enhancement of innovative, minimally invasive, image-guided therapies from inception to mature clinical application and to conduct educational programs in the service of its mission.

What's New

New to the IR Store!

SIR Foundation is putting research and education first with its first product for sale in the IR Store: a long-sleeved SIR Foundation Awareness shirt! Support the Foundation and purchase an awareness shirt. All proceeds go to the Foundation.

Economic Stimulus Package

Economic Stimulus Package Will Provide Billions in Research Funding

View up to date Funding Opportunities

Interventional Oncology (IO) Registry

The Interventional Oncology (IO) Registry is a Web-based registry designed (in Phase 1) to collect 30-day safety data for ablations performed on tumors located in the lung, kidney and bone. Phase 2 of the registry will include long-term follow-up for efficacy, additional anatomical areas of treatment and additional methods of treatment. Phase 3 aims to include measures of quality of life, performance status, image archive, and survival or outcomes analysis.

The IO Registry is the product of the contribution of more than 12 expert interventional radiologists and will ultimately expand to other practitioners around the globe. Five sites performed user acceptance testing in April 2008, and the registry was operational by May 2008. In less than three months, 117 cases were entered from six active sites.

See the IO Registry.

PAD Protocol Development

Experts in peripheral arterial disease (PAD) convened in Herndon, Va., on Sept. 4, 2008, to map out the protocol for a high-level consortium outcomes study to evaluate SFA disease outcomes. The protocol topic was previously determined at the Foundation's April 2008 PAD Research Consensus Panel meeting.

The PAD outcomes study will represent a broad, multiyear survey of the current and future practice of endovascular therapy for SFA disease, as well as the factors influencing current trends. In addition, the study will serve to provide long-term data in the PAD population undergoing various interventions.

Read more about PAD protocol development.

Opportunity to Submit Proposals for Carotid Intervention Research

Members who have an interest in carotid interventions have an opportunity to submit a proposal for academic research leading to an abstract or manuscript. The National Cardiovascular Data Registry (NCDR) Carotid Artery Revascularization and Endarterectomy Registry (CARE) program collects patient, provider and facility characteristics; device and lesion characteristics; adverse event rates, including 30 day follow-up and many more measures. Applicants can request funding from NCDR to perform and pay for all data analysis and statistical work. For more information about the CARE registry and to download a research proposal application

Read more about the CARE registry; a research proposal application may be downloaded here as well.

ATTRACT Trial

In 2004, SIR Foundation's Cooperative Alliance for Interventional Radiology Research (CAIRR) convened a research consensus panel (RCP) in order to discuss and establish a research agenda for endovascular venous thromboembolism (VTE) interventions. The expert panel proposed that the most needed research in VTE was an acute DVT trial. This trial will compare the best medical therapy with the current best interventional clot removal method. The meeting proceedings were published in the Journal of Vascular and Interventional Radiology in 2005.

The SIR Foundation began working with Suresh Vedantham, M.D., from the Washington University School of Medicine in 2006 to develop the federal application for the ATTRACT trial. An NIH R01 application was submitted to the National Heart Lung and Blood Institute (NHLBI) in June 2007. The ATTRACT trial subsequently received $10.2 million in funding. SIR Foundation serves as a collaborating institution on the ATTRACT trial.